Polysaccharide-K (PSK) increases p21WAF/Cip1 and promotes apoptosis in pancreatic cancer cells

Pancreatology

Volumn 12, Issue 6, 2012, Pages 467-474

  Rosendahl, Ann H ^a   Sun, Chen ^a,b   Wu, Dequan Q ^b   Andersson, Roland ^a  

^a LUND UNIVERSITY   (Sweden)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Pancreatic cancer; PSK; TLR

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; GEMCITABINE; KRESTIN; NEUTRALIZING ANTIBODY; PROTEIN BAX; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; UPREGULATION; WESTERN BLOTTING;

EID: 84873085234     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.09.004     Document Type: Article

References (40)

1. Fryer RA, Galustian C, Dalgleish AG. Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol 2009;4: 102-12.
2. Jonckheere N, Fauquette V, Stechly L, Saint-Laurent N, Aubert S, Susini C, et al. Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by ap-2alpha overexpression. Br J Cancer 2009;101:637-44.
3. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007;34:347-53.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
5. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
6. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the united states, 1990-1997: results of a follow-up national survey. J Am Med Assoc 1998;280:1569-75.
7. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/ alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-14.
8. Sun C, Rosendahl AH, Wang XD, Wu DQ, Andersson R. Polysaccharide-k (psk) in cancer e old story, new possibilities? Curr Med Chem 2012;19:757-62.
9. Fisher M, Yang LX. Anticancer effects andmechanisms of polysaccharide-k (psk): implications of cancer immunotherapy. Anticancer Res 2002;22:1737-54.
10. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, et al. Adjuvant immunochemotherapy with oral tegafur/uracil plus psk in patients with stage ii or iii colorectal cancer: a randomised controlled study. Br J Cancer 2004;90:1003-10.
11. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide k for patients with curative resections of gastric cancer. Cancer Immunol Immunother 2007;56: 905-11.
12. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S, et al. Effect of krestin as adjuvant treatment following radical radiotherapy in nonsmall cell lung cancer patients. Cancer Detect Prev 1997;21:71-7.
13. ClinicalTrials.gov. Bethesda (MD): U.S. National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/results?Term~psk+and+cancer; 19 Oct 2011.
14. Liu A, Arbiser JL, Holmgren A, Klein G, Klein E. Psk and trx80 inhibit b-cell growth in ebv-infected cord blood mononuclear cells through t cells activated by the monocyte products il-15 and il-12. Blood 2005;105:1606-13.
15. Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa N. Psk, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol 2002;20: 1189-95.
16. Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, et al. Polysaccharide krestin is a novel tlr2 agonist that mediates inhibition of tumor growth via stimulation of cd8 t cells and nk cells. Clin Cancer Res 2011;17:67-76.
17. Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, et al. Tlr2 agonist psk activates human nk cells and enhances the anti-tumor effect of her2-targeted monoclonal antibody therapy. Clin Cancer Res 2011;17:6742-53.
18. Asai H, Iijima H, Matsunaga K, Oguchi Y, Katsuno H, Maeda K. Protein-bound polysaccharide k augments il-2 production from murine mesenteric lymph node cd4+ t cells by modulating t cell receptor signaling. Cancer Immunol Immunother 2008;57:1647-55.
19. Price LA, Wenner CA, Sloper DT, Slaton JW, Novack JP. Role for toll-like receptor 4 in tnf-alpha secretion by murine macrophages in response to polysaccharide krestin, a trametes versicolor mushroom extract. Fitoterapia 2010;81:914-9.
20. Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S, Shirakusa T. Immunochemotherapy with psk and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm 2008;23:461-7.
21. Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, et al. A randomized phase iii trial of postoperative adjuvant therapy with s-1 alone versus s-1 plus psk for stage ii/iiia gastric cancer: Hokuriku-kinki immunochemo- therapy study group-gastric cancer (hkit-gc). Jpn J Clin Oncol 2006; 36:519-22.
22. Jimenez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, et al. The immunomodulator psk induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 2008; 8:78.
23. Zhang H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K, et al. Protein-bound polysaccharide psk inhibits tumor invasiveness by downregulation of tgf-beta1 and mmps. Clin Exp Metastasis 2000;18:343-52.
24. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011;145:571-83.
25. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998;94:695-8.
26. Pandey S, Agrawal DK. Immunobiology of toll-like receptors: emerging trends. Immunol Cell Biol 2006;84:333-41.
27. Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL. Expression and significance of tlr4 and hif-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010;16:2881-8.
28. Morse DL, Balagurunathan Y, Hostetter G, Trissal M, Tafreshi NK, Burke N, et al. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol 2010;80: 748-54.
29. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, et al. Cancer relapse under chemotherapy: why tlr2/4 receptor agonists can help. Eur J Pharmacol 2007;563:1-17.
30. Kamei H, Hashimoto Y, Koide T, Kojima T, Hasegawa M, Umeda T. Direct tumor growth suppressive effect of melanoidin extracted from immunomodulator- psk. Cancer Biother Radiopharm 1997;12:341-4.
31. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)- dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-4.
32. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. Cd40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-6.
33. Conroy T, Gavoille C, Adenis A. Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 2011;23:390-5.
34. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 2009;69:5575-83.
35. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65:9064-72.
36. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, et al. A phase ii randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 2012;30:1597-606.
37. Zhang H, Morisaki T, Nakahara C, Matsunaga H, Sato N, Nagumo F, et al. Pskmediated nf-kappab inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells nor-p1. Oncogene 2003;22:2088-96.
38. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 2009;44:782-6.
39. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-95.
40. Kariya Y, Inoue N, Kihara T, Okamoto N, Sugie K, Mori T, et al. Activation of human natural killer cells by the protein-bound polysaccharide psk independently of interferon and interleukin 2. Immunol Lett 1992;31: 241-5.